Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
المؤلفون المشاركون
Liu, Ying
Ye, Zhengbao
Xi, Wenqi
Ma, Tao
Shi, Min
Yang, Liu
Zhu, Zhenggang
Zhang, Jun
المصدر
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-09-15
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
To evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the first line treatment of advanced gastric adenocarcinoma.
Methods.
A total of 37 patients were enrolled into this study, and they received DOX regimen (docetaxel 75 mg/m2 and oxaliplatin 130 mg/m2 intravenous infusion on day 1, and capecitabine 1000 mg/m2 orally twice daily on d1–14); treatment was repeated every 3 weeks.
Results.
All 37 patients were assessable for evaluation.
The numbers of patients with complete response (CR), partial responses (PR), stable disease (SD), and progressive disease (PD) were 1, 10, 23, and 3, respectively.
The objective response rate (ORR) was 29.7%, with the disease control rate (DCR) of 91.9%.
Median progression-free survival (mPFS) and overall survival (mOS) were 197 days and 364 days, respectively.
The most common grade 3/4 toxicities were hematological toxicities.
The most common grade 3/4 nonhematological toxicities were fatigue, nausea, vomiting, anorexia, diarrhea, and hand-foot syndrome.
Conclusion.
The DOX regimen demonstrated a promising efficacy as the first line regimen in treating advanced gastric cancer patients with good performance status, the toxicities were tolerated and controllable.
Large-scale clinical observation is necessary to get further evidence.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Liu, Ying& Ye, Zhengbao& Xi, Wenqi& Ma, Tao& Shi, Min& Yang, Liu…[et al.]. 2013. Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma. BioMed Research International،Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-1005542
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Liu, Ying…[et al.]. Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma. BioMed Research International No. 2013 (2013), pp.1-6.
https://search.emarefa.net/detail/BIM-1005542
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Liu, Ying& Ye, Zhengbao& Xi, Wenqi& Ma, Tao& Shi, Min& Yang, Liu…[et al.]. Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-1005542
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1005542
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر